Sinocelltech, Clover Soar as Vaccine Makers’ Covid-19 Jabs Are Approved for Use in China
Tang Shihua
DATE:  Dec 05 2022
/ SOURCE:  Yicai
Sinocelltech, Clover Soar as Vaccine Makers’ Covid-19 Jabs Are Approved for Use in China Sinocelltech, Clover Soar as Vaccine Makers’ Covid-19 Jabs Are Approved for Use in China

(Yicai Global) Dec. 5 -- Shares in Sinocelltech Group and Clover Biopharmaceutical skyrocketed by as much as 13.3 percent and 21.4 percent respectively today after the two Chinese vaccine manufacturers said that their recombinant protein Covid-19 jabs have been greenlit for emergency use in China.

Sinocelltech’s share price [SHA:688520] closed down 0.8 percent at CNY74.40 (USD10.70) as investors cashed in. Earlier in the day it hit CNY85. While Clover’s stock [HKG:2197] closed up 2.7 percent at HKD4.55 (USD0.60), after jumping to HKD5.38 earlier in the day.

Unit Shenzhou Cell Engineering has been informed by authorities that it can take its self-developed recombinant Covid-19 vaccine to market, Beijing-based Sinocelltech said yesterday.

Clover Biopharma’s self-developed recombinant protein Covid-19 jab has been given the nod for emergency use, the Chengdu, southwestern Sichuan province-based company said today, without releasing any details of the clinical trial results.

Recombinant protein vaccines lack infectious components and insert a part of the novel coronavirus protein into the body to help the immune system recognize the virus and fight it off.

Sinocelltech’s clinical trials both at home and abroad have demonstrated that the vaccine is highly effective against existing omicron strains BA.1 and BA.5, and has the potential to work against future variants too, the firm said. The jab confers extremely long immunity and is as safe as inactivated vaccines, which use a killed, rather than attenuated, version of the virus, it added.

Sinocelltech’s factory in Beijing’s economic development zone is now preparing to mass produce the vaccine, the Beijing municipal government said on Dec. 3.

Clover Biopharma’s plant in Changxing, eastern Zhejiang province is ready to start production of the jab, the company said in its initial public offering filing to the Hong Kong Stock Exchange in October last year.

Zhifei Biological Products’ recombinant Covid-19 vaccine was approved by Chinese regulators for emergency use in March, making it the first recombinant novel coronavirus jab to be greenlit in China and the fifth Covid-19 vaccine to be approved in the country. The US’ Novavax is a major developer of recombinant protein vaccines.

Editor: Kim Taylor

Follow Yicai Global on
Keywords:   COVID-19,Recombinant DNA Protein Vaccine,Sinocelltech Group,Clover Biopharmaceuticals